• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.

作者信息

Giacobbe Daniele R, Bassetti Matteo

机构信息

Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS, Genoa, 16132, Italy.

Department of Health Sciences, University of Genoa, Genoa, 16132, Italy.

出版信息

Future Microbiol. 2022 Apr;17:393-396. doi: 10.2217/fmb-2021-0301. Epub 2022 Mar 2.

DOI:10.2217/fmb-2021-0301
PMID:35234517
Abstract
摘要

相似文献

1
Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.用于耐碳青霉烯类革兰氏阴性菌的新型β-内酰胺/β-内酰胺酶抑制剂组合
Future Microbiol. 2022 Apr;17:393-396. doi: 10.2217/fmb-2021-0301. Epub 2022 Mar 2.
2
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.头孢地尔肟与新型β-内酰胺/β-内酰胺酶抑制剂组合对高、低通透性条件下表达单种和双种β-内酰胺酶的同源大肠埃希菌的活性。
Int J Antimicrob Agents. 2024 May;63(5):107150. doi: 10.1016/j.ijantimicag.2024.107150. Epub 2024 Mar 19.
3
Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?对头孢地尔敏感性降低/耐药的多重耐药革兰氏阴性临床分离株：目前和未来最佳的治疗替代方案有哪些？
Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):339-354. doi: 10.1007/s10096-023-04732-4. Epub 2023 Dec 14.
4
activity of cefiderocol against European and spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.头孢地尔罗对欧洲肠杆菌科和铜绿假单胞菌的活性，包括对美罗培南和最近的β-内酰胺/β-内酰胺酶抑制剂组合耐药的分离株。
Microbiol Spectr. 2024 Apr 2;12(4):e0383623. doi: 10.1128/spectrum.03836-23. Epub 2024 Mar 14.
5
New β-Lactam-β-Lactamase Inhibitor Combinations.新型β-内酰胺类-β-内酰胺酶抑制剂复方制剂
Clin Microbiol Rev. 2020 Nov 11;34(1). doi: 10.1128/CMR.00115-20. Print 2020 Dec 16.
6
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.β-内酰胺/替加环素（VNRX-5133）联合用药对碳青霉烯类耐药革兰氏阴性菌的活性。
J Antimicrob Chemother. 2021 Jan 1;76(1):160-170. doi: 10.1093/jac/dkaa391.
7
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.新型β-内酰胺酶抑制剂他尼硼巴坦与头孢吡肟或美罗培南对肺炎克雷伯菌的体外比较活性以及头孢吡肟对产金属β-内酰胺酶的铜绿假单胞菌临床分离株的体外比较活性。
Int J Antimicrob Agents. 2021 Nov;58(5):106440. doi: 10.1016/j.ijantimicag.2021.106440. Epub 2021 Sep 20.
8
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.获得性广谱β-内酰胺酶对大肠埃希菌和铜绿假单胞菌中新型β-内酰胺类（氨曲南、头孢吡肟、美罗培南和亚胺培南）和新型β-内酰胺酶抑制剂组合药物敏感性的影响。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31.
9
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.新型β-内酰胺酶抑制剂他尼硼巴坦（VNRX-5133）联合头孢吡肟或美罗培南对来自中国的多重耐药革兰氏阴性菌分离株的体外活性。
J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. doi: 10.1093/jac/dkaa053.
10
Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant .美罗培南-ANT3310，一种独特的β-内酰胺-β-内酰胺酶抑制剂组合，具有针对革兰氏阴性病原体（包括耐碳青霉烯类的）的广谱抗菌活性。
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0112023. doi: 10.1128/aac.01120-23. Epub 2024 Jan 30.

引用本文的文献

1
A comprehensive investigation of the medicinal efficacy of antimicrobial fusion peptides expressed in probiotic bacteria for the treatment of pan drug-resistant (PDR) infections.全面研究益生菌中表达的抗菌融合肽在治疗泛耐药（PDR）感染方面的药效。
Arch Microbiol. 2024 Feb 8;206(3):93. doi: 10.1007/s00203-023-03823-2.
2
Treatment and diagnosis of severe KPC-producing infections: a perspective on what has changed over last decades.严重产 KPC 感染的治疗和诊断：近几十年来的变化视角。
Ann Med. 2023 Dec;55(1):101-113. doi: 10.1080/07853890.2022.2152484.
3
Current and Emerging Treatment Options for Multidrug Resistant Urosepsis: A Review.
多重耐药性泌尿道感染的当前及新出现的治疗选择：综述
Antibiotics (Basel). 2022 Dec 15;11(12):1821. doi: 10.3390/antibiotics11121821.